SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-062878
Filing Date
2024-03-08
Accepted
2024-03-08 07:10:02
Documents
15
Period of Report
2024-03-08
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d787565d8k.htm   iXBRL 8-K 31441
2 EX-99.1 d787565dex991.htm EX-99.1 30783
  Complete submission text file 0001193125-24-062878.txt   194128

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA amlx-20240308.xsd EX-101.SCH 2847
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE amlx-20240308_lab.xml EX-101.LAB 17235
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE amlx-20240308_pre.xml EX-101.PRE 10810
16 EXTRACTED XBRL INSTANCE DOCUMENT d787565d8k_htm.xml XML 3505
Mailing Address 43 THORNDIKE STREET CAMBRIDGE MA 02141
Business Address 43 THORNDIKE STREET CAMBRIDGE MA 02141 617-683-0917
Amylyx Pharmaceuticals, Inc. (Filer) CIK: 0001658551 (see all company filings)

IRS No.: 464600503 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41199 | Film No.: 24732322
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)